Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.

Conditions

• Blister
• Wound of Skin
• Epidermolysis Bullosa
• Varicose Ulcer of Lower Limb

Interventions

• DRUG: TCP-25 gel 0.86 mg/ml or placebo gel
• DRUG: TCP-25 gel 2.9 mg/ml or placebo gel
• DRUG: TCP-25 gel 8.6 mg/ml or placebo gel

Sponsor

Xinnate AB

Collaborators

• [object Object]